Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.
Epistemonikos ID: fc5711788e532c7a9aacf4b5c95108bc94ab70d0
First added on: May 11, 2024